Lexicon Pharmaceuticals earnings were -$61.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest LXRX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$31.8M, up 2,946.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LXRX reported annual earnings of -$50.3M, with -74.9% growth. The next LXRX earnings date is Nov 5, 2026.
Lexicon Pharmaceuticals Earnings Reports & History FAQ
What were Lexicon Pharmaceuticals's earnings last quarter?
On LXRX's earnings call on Aug 6, 2026, Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 2026 earnings per share (EPS) of -$0.07, up 800% year over year. Total LXRX earnings for the quarter were -$31.78 million. In the same quarter last year, Lexicon Pharmaceuticals's earnings per share (EPS) was $0.01.
When does Lexicon Pharmaceuticals report earnings?
The next LXRX earnings date is Nov 5, 2026. Add LXRX to your watchlist to be reminded of Lexicon Pharmaceuticals's next earnings date.
Is Lexicon Pharmaceuticals profitable or losing money?
As of the last Lexicon Pharmaceuticals earnings report, Lexicon Pharmaceuticals is currently losing money. Lexicon Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$61.12 million, a 49.33% decrease year over year.
What was LXRX's earnings growth in the past year?
As of Lexicon Pharmaceuticals's earnings date in Aug 6, 2026, Lexicon Pharmaceuticals's earnings has grown year over year. LXRX earnings in the past year totalled -$61.12 million.
What are Lexicon Pharmaceuticals's earnings expectations?
The current EPS estimate for Lexicon Pharmaceuticals's earnings report in Nov 5, 2026 is -$0.05.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.